Tideglusib, a thiadiazolone that irreversibly inhibits GSK-3β and reduces tau phosphorylation, did not show any clinical benefit in a double-blind, placebo-controlled Phase II trial demonstrating the clinical efficacy of GSK-3 inhibitors in AD and is subject to further study (Lovestone et al., 2015). This evidence concerns the gene GSK3B and Alzheimer disease.